Chronic hepatitis C
Conditions
Interventions
A group (IL28B CC genotyp ):Peg-IFN plus ribavirin for 48 weeks
B group (IL28B CC genotyp):Peg-IFN plus ribavirin for 36 weeks
C group (IL28B TT/CT genotyp):Peg-IFN plus ribavirin for 48 weeks
D group (IL28B TT/CT genotyp):Peg-IFN plus ribavirin for 72 weeks
Sponsors
Third Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients between 18 and 55 years old, Gender are not limited; 2. Serum anti-HCV antibody (+) and HCVRNA >=10^3 copies/mL; 3. Peripheral hemogram: WBC >=3*10^9/L, Neutrophil count >=1.5*10^9/L, Platelet count >=80*10^9/L, Hemoglobin > 80g /L; 4. Baseline ALT<=10-fold upper limit of nomal and TBIL <=34.2 umol/L; 5. Albumin is normal; 6. Serum creatinine <=132umol/L; 7. Fasting glucose <=7mmol/L; 8. Autoimmune antibody is negative; 9. Thyroid function is normal; 10. Serum lipids is nomal; 11. Alpha-Fetalprotein <=100ng/ml; 12. Has not received anti-HCV therapy in the past six months; 13. Subjects must understand and sign written informed consent form and abide by the requirements of this study.
Exclusion criteria
Exclusion criteria: 1. Woman in pregnancy or breast-feeding; 2. Patient who received the treatment of any interferon or immune modulator in the past 6 months; 3. Patient who is allergic to interferon or ribaviron; 4. Patient with decompensated liver diseases; 5. Patient who is coinfection with HBV or HIV; 6. Patient who has a history of autoimmune disease; 7. Patient who has uncontrolled heart disease; 8. Patient with severe retinitis or past history of retinitis; 9. Patient with uncontrolled thyroid disease; 1 10. Patient who is current drug abuse or alcohol abuse; 11. Patient with a current or past history of psychiatric disease; 12. Patient with uncontrolled diabetes mellitus or hypertension; 13. Patient with obesity; 14. Patient plans to receive or has received organ transplantation; 15. Patient with malignant tumor; 16. Patient with severe kidney disease or bone-marrow suppression; 17. Patient who may receive intravenous steroid therapy during the study; 18. Patietn who can not comply with the treatment protocol; 19. Patient who's not appropriate to take part in this study in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL28B;sustained virological response; | — |
Countries
China
Contacts
Public ContactXiaohong Wang
Outcome results
None listed